Skip to main content

This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

Explore our Expert Encounter series focused on Atopic Dermatitis. Uncover new strategies for managing comorbidities, learn about the latest evidence supporting disease-modifying therapies, and gain practical guidance for implementing these approaches in your clinical practice.

Exploring Disease Modification in Atopic Dermatitis: Insights from International Experts

In this enlightening Q&A session, dermatology experts Professor Cork and Professor Thaçi share their valuable insights on the evolving landscape of Atopic Dermatitis treatment, with a focus on disease modification.

These videos offer valuable perspectives for dermatologists and healthcare professionals seeking to optimise their approach to managing atopic dermatitis, particularly in cases where traditional treatments have not provided adequate control.

Atopic March to Modification: The Type 2 Connection

A Sanofi/Regeneron sponsored symposium presented at the British Association of Dermatologists Annual Meeting, 2026.

This symposium, chaired by Dr. Andrew Pink and Prof Michael Arden-Jones highlights, from a patient perspective, the importance of treatment pathways, the impact of type 2 inflammation and how overall disease burden opens up the possibility of on-therapy disease modification.

Discover other resources  

Photo of the paper ADCT test

Atopic Dermatitis Control Test (ADCT)

Atopic dermatitis, a type of eczema, may be affecting your patient’s life in more ways than you know.

The ADCT gives a measure of how controlled your patient’s eczema is. Use these 6 concise questions to evaluate all dimensions of atopic dermatitis control.

Development of ADCT involved literature review as well as interviews with patients and physicians, and was funded by Sanofi and Regeneron.

Try the ADCT

MAT-XU-2503952 (v2.0) Date of preparation: October 2026